MAP Pharmaceuticals, Inc. (MAPP) Reports Q1 EPS Loss of $0.58
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Join SI Premium – FREE
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q1 EPS of ($0.58), $0.19 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $34.2 million, which may not compare to the consensus estimate of $820 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
- nCino, Inc. (NCNO) Reports Q2 EPS of $0.05, Offers Guidance
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
